A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641).

Kim N. Chi,Dana E. Rathkopf,Gerhardt Attard,Matthew R. Smith,Eleni Efstathiou,David Olmos,Eric J. Small,Ji Youl Lee,Paul Sieber,Curtis Dunshee,Deborah Ricci,Jason S. Simon,Xin Zhao,Nishi Kothari,Shinta Cheng,Shahneen Sandhu

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641).

2020

Kim N. Chi
Dana E. Rathkopf
Gerhardt Attard
Matthew R. Smith
Eleni Efstathiou
David Olmos
Eric J. Small
Ji Youl Lee
Paul Sieber
Curtis Dunshee
Deborah Ricci
Jason S. Simon
Xin Zhao
Nishi Kothari
Shinta Cheng
Shahneen Sandhu

TPS257Background: Preclinical data suggest synergistic antitumor activity when the PARP inhibitor (PARPi) niraparib is combined with the androgen pathway inhibitor abiraterone acetate. (1) The addi...

Keywords:

Urology
Prostate cancer
Prednisone
Abiraterone acetate
Pathology
Placebo
double blind
Medicine
PARP inhibitor
Internal medicine
Oncology
Androgen
in patient
double blind study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations